Anokion

Ecublens, Switzerland Founded: 2010 • Age: 16 yrs
Therapeutic proteins are developed for autoimmune and allergic disease treatment.
Request Access

About Anokion

Anokion is a company based in Ecublens (Switzerland) founded in 2010.. Anokion has raised $112.5 million across 3 funding rounds from investors including Pfizer, Celgene and Novo Holdings. The company has 30 employees as of December 31, 2023. Anokion has completed 1 acquisition, including Kanyos Bio. Anokion offers products and services including SynCeD, ACeD-it, ACeD, and MoveS-it. Anokion operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and Vir Biotechnology, among others.

  • Headquarter Ecublens, Switzerland
  • Employees 30 as on 31 Dec, 2023
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Anokion Us Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $112.5 M (USD)

    in 3 rounds

  • Latest Funding Round
    $35 M (USD), Series B

    Oct 18, 2022

  • Investors
    Pfizer

    & 4 more

  • Employee Count
    30

    as on Dec 31, 2023

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Anokion

Anokion offers a comprehensive portfolio of products and services, including SynCeD, ACeD-it, ACeD, and MoveS-it. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform for celiac disease treatment via immune tolerance.

Targets celiac disease with antigen-specific interventions.

Focuses on celiac disease immune tolerance therapies.

Develops treatments for multiple sclerosis using tolerance methods.

People of Anokion
Headcount 10-50
Employee Profiles 2
Board Members and Advisors 10
Employee Profiles
People
Glenn Booma
Chief Strategy Officer

Unlock access to complete

Board Members and Advisors
people
Patricia L. Allen
Director
people
Laura Brass
Director
people
Vladimir R. Muzykantov
Scientific Advisor
people
David P. Nowotnik
Scientific Advisor

Unlock access to complete

Funding Insights of Anokion

Anokion has successfully raised a total of $112.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series B — $35.0M
  • First Round

    (09 May 2014)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2022 Amount Series B - Anokion Valuation Pfizer
Sep, 2019 Amount Series B - Anokion Valuation Celgene
May, 2014 Amount Series A - Anokion Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Anokion

Anokion has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Celgene and Novo Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity and venture capital fund focused on the healthcare sector
Founded Year Domain Location
Investments are made in innovative life science companies globally.
Founded Year Domain Location
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Anokion

Anokion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kanyos Bio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease
2015
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Anokion

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Anokion Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Anokion

Anokion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and Vir Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Developer of therapeutics for the treatment of infectious diseases
domain founded_year HQ Location
Plasma-based biologics are developed for immune deficiency and infectious diseases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Anokion

Frequently Asked Questions about Anokion

When was Anokion founded?

Anokion was founded in 2010 and raised its 1st funding round 4 years after it was founded.

Where is Anokion located?

Anokion is headquartered in Ecublens, Switzerland. It is registered at Ecublens, Vaud, Switzerland.

Is Anokion a funded company?

Anokion is a funded company, having raised a total of $112.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $37.5M, raised on May 09, 2014.

How many employees does Anokion have?

As of Dec 31, 2023, the latest employee count at Anokion is 30.

What does Anokion do?

Anokion was founded in 2010 in Ecublens, Switzerland, within the biotechnology sector. Therapeutic proteins are developed using antigen-specific immune tolerance technology to address autoimmune and allergic diseases. The platform is designed to reduce immunogenicity of proteins and enable treatments across various clinical indications. Operations focus on translating this technology to multiple protein-based therapies for immune-related conditions.

Who are the top competitors of Anokion?

Anokion's top competitors include Moderna, BeiGene and ADMA Biologics.

What products or services does Anokion offer?

Anokion offers SynCeD, ACeD-it, ACeD, and MoveS-it.

How many acquisitions has Anokion made?

Anokion has made 1 acquisition, including Kanyos Bio.

Who are Anokion's investors?

Anokion has 5 investors. Key investors include Pfizer, Celgene, Novo Holdings, Novartis Venture Fund, and Versant Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available